Child-Pugh Score Calculator (Child-Turcotte-Pugh / CTP)
Calculate the standard five-domain Child-Turcotte-Pugh score and class for established cirrhosis using bilirubin, albumin, INR or PT prolongation, ascites, and encephalopathy.
Content updated: View sources
QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.
Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.
Scope before scoring
Use this standard Child-Pugh/CTP table for established cirrhosis or when an applicable protocol explicitly requires CTP class. The calculator does not diagnose cirrhosis.
Child-Pugh / CTP Scoring Criteria
Select one published 1-, 2-, or 3-point band for each of the five domains. INR and PT prolongation are alternative expressions of one coagulation domain, never two separate scores. [1, 2, 3]
- Criterion
- Total bilirubin
- 1 point
- <2 mg/dL (<34.2 µmol/L)
- 2 points
- 2–3 mg/dL (34.2–51.3 µmol/L)
- 3 points
- >3 mg/dL (>51.3 µmol/L)
- Criterion
- Serum albumin
- 1 point
- >3.5 g/dL (>35 g/L)
- 2 points
- 2.8–3.5 g/dL (28–35 g/L)
- 3 points
- <2.8 g/dL (<28 g/L)
- Criterion
- Coagulation
- 1 point
- INR: <1.7PT prolongation: <4 seconds prolonged
- 2 points
- INR: 1.7–2.3PT prolongation: 4–6 seconds prolonged
- 3 points
- INR: >2.3PT prolongation: >6 seconds prolonged
- Criterion
- Ascites
- 1 point
- None
- 2 points
- Mild/moderate and diuretic-responsive
- 3 points
- Severe and diuretic-refractory
- Criterion
- Hepatic encephalopathy
- 1 point
- None
- 2 points
- Grade 1–2 or precipitant-induced
- 3 points
- Grade 3–4 or chronic
About
The Child-Turcotte-Pugh (CTP) score is a five-domain categorical score used for established cirrhosis and in protocols that explicitly request CTP class. This page implements the standard table published by the U.S. Department of Veterans Affairs and accepts either INR or prothrombin-time prolongation as the single coagulation domain. [1, 2, 4]
It does not diagnose cirrhosis, calculate the current U.S. transplant-allocation score, estimate an individual survival probability, or decide surgery, medication eligibility, dose, monitoring, referral, admission, or treatment. Current U.S. liver allocation uses MELD rather than conversion of a CTP class. [9, 11, 13]
Interpretation
What the five domains mean
Bilirubin reflects pigment clearance and excretion; albumin is a circulating protein synthesized by the liver; INR or PT prolongation reflects the selected coagulation measure; ascites is fluid in the abdomen; and hepatic encephalopathy is brain dysfunction attributed to liver disease. A laboratory result cannot substitute for the documented clinical grading of ascites or encephalopathy. [2, 6, 7]
Use one documented clinical time point
Use laboratory and examination findings from the intended assessment time. Albumin infusion, anticoagulants, plasma products, diuretics, paracentesis, lactulose, rifaximin, sedation, intubation, infection, bleeding, kidney injury, and other acute events can change or confound one or more domains. Record those circumstances instead of treating the score as context-free. [4, 5, 8]
INR and PT are alternatives
Choose one coagulation basis. PT prolongation means seconds above the laboratory control, not the patient’s raw PT. INR and PT bands must not both be added. Anticoagulant-associated INR elevation can make the standard score misleading. [2, 4, 11]
Ascites and encephalopathy are treatment-sensitive
The standard table distinguishes diuretic-responsive from diuretic-refractory ascites and grades encephalopathy using documented clinical severity. These domains introduce subjectivity and can change after treatment, so a score should identify who graded it, when, and under what treatment state. [5, 6, 7, 8]
Important model limitations
Ascites and encephalopathy are partly subjective and can vary between observers. The three laboratory domains collapse continuous values into only three bands, the score does not include renal function, and treatment can change several domains. These are limitations of the model rather than software corrections this calculator can infer. [2, 4, 5]
CTP and MELD answer different questions
CTP includes two clinical judgments and three categorical laboratory domains. MELD models use different variables and equations. The current U.S. allocation system does not arise by converting a CTP class. For a separate version-specific MELD calculation, see the MELD 3.0, MELD-Na & Classic MELD calculator. [9, 13]
Class is not an individualized prognosis
Higher Child-Pugh class generally reflects greater cirrhosis severity and has prognostic associations, but outcomes vary by population, era, cause of cirrhosis, decompensation state, renal dysfunction, infection, procedure, treatment, endpoint, and follow-up. This calculator does not convert class into an individualized survival or perioperative mortality probability. [4, 9, 10]
Child-Pugh is not a universal drug-dosing system
Some medicine labels and hepatic-impairment pharmacokinetic studies use CTP class. FDA's 2003 final guidance historically used Child-Pugh classification for this study purpose; FDA withdrew it when issuing a September 2026 replacement draft, which is explicitly not for implementation and discusses both Child-Pugh and NCI criteria. NHS SPS likewise notes that no single validated scoring system determines medication dosing in cirrhosis. Drug-specific labeling and current applicable guidance determine whether and how CTP class is used; this calculator does not select a medicine, dose, contraindication, or monitoring plan. [3, 11, 12]
References
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–649. PMID 4541913. DOI 10.1002/bjs.1800600817.
- U.S. Department of Veterans Affairs. Child-Turcotte-Pugh (CTP) Calculator — Cirrhosis. Standard five-domain table and class boundaries.
- NHS Specialist Pharmacy Service. Calculating and using the Child-Pugh score. Published May 17, 2024; updated June 14, 2024. Standard five-parameter table, class ranges, medicine-label context, and dosing limitations.
- Garcia-Tsao G. The Child-Turcotte Classification: From Gestalt to Sophisticated Statistics and Back. Clin Liver Dis (Hoboken). 2016;8(6):149–151. PMID 27696097. PMCID PMC5218597.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. PMID 29653741. DOI 10.1016/j.jhep.2018.03.024.
- Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–1048. PMID 33942342. DOI 10.1002/hep.31884.
- Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL. Hepatology. 2014;60(2):715–735. PMID 25042402. DOI 10.1002/hep.27210.
- de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII — Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. PMID 35120736. PMCID PMC11090185. DOI 10.1016/j.jhep.2021.12.022.
- Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: the model for end-stage liver disease — should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–1089. PMID 16305721. DOI 10.1111/j.1365-2036.2005.02691.x.
- D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–231. PMID 16298014. DOI 10.1016/j.jhep.2005.10.013.
- U.S. Food and Drug Administration. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Historical final guidance. May 2003. Docket FDA-1999-D-0063; withdrawn when the September 2026 draft was issued.
- U.S. Food and Drug Administration. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage. Draft Guidance for Industry. September 2026. Draft — Not for Implementation. Docket FDA-2026-D-8693.
- HRSA/OPTN MELD calculator, reviewed December 2025. Current U.S. liver allocation uses the MELD model rather than conversion of a Child-Pugh class.
FAQ
No. Some product labels and hepatic-impairment studies refer to CTP class, but there is no universal Child-Pugh dosing algorithm. FDA's September 2026 replacement guidance is a draft not for implementation, and NHS SPS recommends medicine-, patient-, and context-specific assessment. This calculator does not select, prescribe, or adjust medication.
Related Calculators
MELD 3.0
Calculate current OPTN MELD 3.0 for age 12+ or reproduce historical MELD-Na and classic MELD with version-specific inputs and limits.
SAAG
Calculate the signed SAAG from same-day serum and ascitic-fluid albumin, with independent units and non-diagnostic interpretation limits.
APRI
Calculate APRI from same-assessment AST, the reporting laboratory’s AST upper limit, and platelet count, with current HCV/HBV context and non-diagnostic limits.
Disclaimer
Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.